These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
146 related items for PubMed ID: 17367883
1. Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure. Ozasa N, Morimoto T, Furukawa Y, Shizuta S, Nishiyama K, Kita T, Kimura T. Int J Cardiol; 2008 Jan 11; 123(2):213-6. PubMed ID: 17367883 [Abstract] [Full Text] [Related]
2. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S. J Am Coll Cardiol; 2006 Jul 04; 48(1):112-21. PubMed ID: 16814657 [Abstract] [Full Text] [Related]
3. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Am Heart J; 2007 Nov 04; 154(5):899-907. PubMed ID: 17967596 [Abstract] [Full Text] [Related]
6. Impact of sleep-disordered breathing on life-threatening ventricular arrhythmia in heart failure patients with implantable cardioverter-defibrillator. Serizawa N, Yumino D, Kajimoto K, Tagawa Y, Takagi A, Shoda M, Kasanuki H, Hagiwara N. Am J Cardiol; 2008 Oct 15; 102(8):1064-8. PubMed ID: 18929710 [Abstract] [Full Text] [Related]
11. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. Costantini O, Hohnloser SH, Kirk MM, Lerman BB, Baker JH, Sethuraman B, Dettmer MM, Rosenbaum DS, ABCD Trial Investigators. J Am Coll Cardiol; 2009 Feb 10; 53(6):471-9. PubMed ID: 19195603 [Abstract] [Full Text] [Related]
12. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. Salerno-Uriarte JA, De Ferrari GM, Klersy C, Pedretti RF, Tritto M, Sallusti L, Libero L, Pettinati G, Molon G, Curnis A, Occhetta E, Morandi F, Ferrero P, Accardi F, ALPHA Study Group Investigators. J Am Coll Cardiol; 2007 Nov 06; 50(19):1896-904. PubMed ID: 17980258 [Abstract] [Full Text] [Related]
13. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. Shah B, Hernandez AF, Liang L, Al-Khatib SM, Yancy CW, Fonarow GC, Peterson ED, Get With The Guidelines Steering Committee. J Am Coll Cardiol; 2009 Feb 03; 53(5):416-22. PubMed ID: 19179199 [Abstract] [Full Text] [Related]
14. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C. Arch Intern Med; 2009 Sep 14; 169(16):1500-6. PubMed ID: 19752408 [Abstract] [Full Text] [Related]
18. Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices. Lin G, Rea RF, Hammill SC, Hayes DL, Brady PA. Heart; 2008 Feb 14; 94(2):186-90. PubMed ID: 17761506 [Abstract] [Full Text] [Related]